JP2023518299A - 小分子エナンチオマーによるアンドロゲン受容体調節 - Google Patents

小分子エナンチオマーによるアンドロゲン受容体調節 Download PDF

Info

Publication number
JP2023518299A
JP2023518299A JP2022556587A JP2022556587A JP2023518299A JP 2023518299 A JP2023518299 A JP 2023518299A JP 2022556587 A JP2022556587 A JP 2022556587A JP 2022556587 A JP2022556587 A JP 2022556587A JP 2023518299 A JP2023518299 A JP 2023518299A
Authority
JP
Japan
Prior art keywords
compound
eitm
nmr
mhz
bms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556587A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021189051A5 (https=
JP2023518299A5 (https=
Inventor
イー． マッケンンナ、チャールズ
ビー． エイガス、デイヴィッド
Original Assignee
ユニバーシティー オブ サウザン カリフォルニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー オブ サウザン カリフォルニア filed Critical ユニバーシティー オブ サウザン カリフォルニア
Publication of JP2023518299A publication Critical patent/JP2023518299A/ja
Publication of JPWO2021189051A5 publication Critical patent/JPWO2021189051A5/ja
Publication of JP2023518299A5 publication Critical patent/JP2023518299A5/ja
Priority to JP2025139537A priority Critical patent/JP2025183239A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022556587A 2020-03-20 2021-03-22 小分子エナンチオマーによるアンドロゲン受容体調節 Pending JP2023518299A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025139537A JP2025183239A (ja) 2020-03-20 2025-08-25 小分子エナンチオマーによるアンドロゲン受容体調節

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062992668P 2020-03-20 2020-03-20
US62/992,668 2020-03-20
PCT/US2021/023512 WO2021189051A1 (en) 2020-03-20 2021-03-22 Androgen receptor regulation by small molecule enantiomers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025139537A Division JP2025183239A (ja) 2020-03-20 2025-08-25 小分子エナンチオマーによるアンドロゲン受容体調節

Publications (3)

Publication Number Publication Date
JP2023518299A true JP2023518299A (ja) 2023-04-28
JPWO2021189051A5 JPWO2021189051A5 (https=) 2024-04-03
JP2023518299A5 JP2023518299A5 (https=) 2024-04-03

Family

ID=77771673

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022556587A Pending JP2023518299A (ja) 2020-03-20 2021-03-22 小分子エナンチオマーによるアンドロゲン受容体調節
JP2025139537A Pending JP2025183239A (ja) 2020-03-20 2025-08-25 小分子エナンチオマーによるアンドロゲン受容体調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025139537A Pending JP2025183239A (ja) 2020-03-20 2025-08-25 小分子エナンチオマーによるアンドロゲン受容体調節

Country Status (4)

Country Link
US (1) US20260103470A1 (https=)
EP (1) EP4121044A4 (https=)
JP (2) JP2023518299A (https=)
WO (1) WO2021189051A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025183239A (ja) * 2020-03-20 2025-12-16 ユニバーシティー オブ サウザン カリフォルニア 小分子エナンチオマーによるアンドロゲン受容体調節

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12552806B2 (en) 2020-03-20 2026-02-17 University Of Southern California Androgen receptor regulation by small molecule enantiomers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523257A (ja) * 2001-12-19 2005-08-04 ブリストル−マイヤーズ　スクイブ　カンパニー 核ホルモン受容体機能の調節剤である、縮合ヘテロ環コハク酸イミド化合物およびその類似体
WO2020211822A1 (zh) * 2019-04-18 2020-10-22 成都海创药业有限公司 一类靶向降解雄激素受体的双功能嵌合体杂环化合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2008157291A2 (en) * 2007-06-15 2008-12-24 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (3Aα, 4β, 5α, 7β, 7Aα)-4-(OCTAHYDRO-5-ETHYLSULFONAMIDO-4,7-DIMETHYL-1,3-DIOXO-4,7-EPOXY-2H-ISOINDOL-2-YL)-2-(TRIFLUOROMETHYL)BENZONITRILE AND METHOD OF PREPARATION
CN102481294A (zh) * 2009-09-11 2012-05-30 拜耳医药股份有限公司 作为抗癌药物的取代(杂芳基甲基)乙内酰硫脲
WO2021189051A1 (en) * 2020-03-20 2021-09-23 University Of Southern California Androgen receptor regulation by small molecule enantiomers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523257A (ja) * 2001-12-19 2005-08-04 ブリストル−マイヤーズ　スクイブ　カンパニー 核ホルモン受容体機能の調節剤である、縮合ヘテロ環コハク酸イミド化合物およびその類似体
WO2020211822A1 (zh) * 2019-04-18 2020-10-22 成都海创药业有限公司 一类靶向降解雄激素受体的双功能嵌合体杂环化合物及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BALOG, A. ET AL.: "Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer", MEDICINAL CHEMISTRY LETTERS, vol. 6, JPN6025007666, 2015, pages 908 - 912, ISSN: 0005536704 *
KATHERIN PATSCH; ET AL: "PARADOXICAL ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS", PNAS, vol. 118, JPN5023006761, 19 March 2021 (2021-03-19), pages 2100918118 - 1, ISSN: 0005536705 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025183239A (ja) * 2020-03-20 2025-12-16 ユニバーシティー オブ サウザン カリフォルニア 小分子エナンチオマーによるアンドロゲン受容体調節

Also Published As

Publication number Publication date
WO2021189051A1 (en) 2021-09-23
US20260103470A1 (en) 2026-04-16
EP4121044A1 (en) 2023-01-25
JP2025183239A (ja) 2025-12-16
EP4121044A4 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
AU2017245125B2 (en) Heterocyclic compound
EP3677584A1 (en) Compound having bruton's tyrosine kinase (btk)-inhibition and degradation activity
US9802945B2 (en) Imidazopyridazine derivatives as modulators of the GABAA receptor activity
WO2017087858A1 (en) Pyrazole compounds and methods of making and using same
US20110053982A1 (en) Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
KR20090130061A (ko) 트리아졸로피리딘 카르복스아미드 유도체 및 트리아졸로피리미딘 카르복스아미드 유도체, 그의 제조 및 그의 치료학적 용도
WO2019065791A1 (ja) 複素環化合物
JPWO2017170830A1 (ja) 複素環化合物
JP2025183239A (ja) 小分子エナンチオマーによるアンドロゲン受容体調節
JPWO2008084717A1 (ja) 三環性化合物およびその医薬用途
US9108977B2 (en) Benzazepine compound
US20150250785A1 (en) Tropomyosin-Related Kinase Inhibitors
JP6134654B2 (ja) 複素環化合物およびその用途
WO2016067143A1 (en) N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
US10538523B2 (en) 4-(biphen-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain
CN109422753A (zh) 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物
WO2020257733A1 (en) Histone demethylase inhibitors for treating cancers
AU2009301797B2 (en) Indazole derivative
US12552806B2 (en) Androgen receptor regulation by small molecule enantiomers
US7863276B2 (en) Salts of modulators of PPAR and methods of treating metabolic disorders
US8008506B2 (en) Indazole compounds
EP1908752A1 (en) Novel 2-quinolone derivative
JP7713954B2 (ja) 核内受容体に対して活性な化合物
CN121712748A (zh) 作为sstr4激动剂的(2s,5r)-5-(羟甲基)吗啉-2-甲酰胺
WO2016009296A1 (en) N-acylpiperidine ether tropomyosin-related kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250912